Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Pr Dr Markus Preising

In this page

Member info

Pr Dr Markus Preising

Representative

Germany

Working Group(s): Retinal Rare Eye Diseases (WG1), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)

Team

MD PhD Lyubomyr Lytvynchuk

Germany

Anterior Segment Rare Eye Diseases (WG4), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Dr Monika Andrassi-Darida

Germany

Pediatric Ophthalmology Rare Diseases (WG3)
See more

Dr Christoph Friedburg

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Retinal Rare Eye Diseases (WG1)
See more

HCP Center

Clinics and institutes Gießen Campus of UKGM is a primary care clinic integrating the full spectrum of medical subspecialities and...

contact

Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany

Klinik und Poliklinik für Augenheilkunde Friedrichstr. 18
35392 Gießen
Germany

Clinical trials

NCT04855045 Unknown

An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects G (p.Cys998X) Mutation.

Interventional
See the trial
voir la fiche
NCT05698316 Recruiting, Active

A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression: (INTERCEPT-AMD)

Observational
See the trial
voir la fiche

NCT03144999 Completed

A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy

Interventional
See the trial
voir la fiche
2020-000681-42 Recruiting, Active

Long-term need of the drug ranibizumab applied as injection into the eye with or without early targeted peripheral laser photocoagulation of the retina for treatment of macular edema due to central retinal vein occlusion

Interventional
See the trial
voir la fiche
NCT03913143 Active, Not recruiting

A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).

Interventional
See the trial
voir la fiche
NCT03297515 Completed

Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (MADEOS).

Interventional
See the trial
voir la fiche
NCT02796274 Completed

Historical Case Record Survey of Visual Acuity Data From Patients With Leber’s Hereditary Optic Neuropathy (LHON).

Interventional
See the trial
voir la fiche
NCT05811351 Recruiting, Active

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Interventional
See the trial
voir la fiche
NCT04939571 Recruiting, Active

European Disease Registry on Retinopathy of Prematurity (ROP)

Observational
See the trial
voir la fiche

Scientific publications

The landscape of submicroscopic structural variants at the OPN1LW/OPN1MW gene cluster on Xq28 underlying blue cone monochromacy

Using parsimonious assumptions, we reconstructed the composition and copy number of the OPN1LW/ OPN1MW gene cluster prior to the mutation event...